SNCA and Parkinson disease: All of this data would therefore suggest that that B cells are activated in Parkinson’s disease, particularly in those at highest risk of disease progression and that this is associated with a reduction in circulating B cells, either due to their exit from the blood (potentially to the CNS or gut, where alpha-synuclein pathology is well-described43) or due to activation-induced cell death.